Evidence map›Paper›PMID 28885610›Full record

ArticleBlood cancer journal2017

In silico and preclinical drug screening identifies dasatinib as a targeted therapy for T-ALL.

S Laukkanen, T Grönroos, P Pölönen, H Kuusanmäki, J Mehtonen, J Cloos, G Ossenkoppele, B Gjertsen, B Øystein, C Heckman and 3 more

Registry-linked trialAbstract readLetter
PubMed Full text at PMC Publisher
In one paragraph

Article in Blood cancer journal, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05681260 (A Randomized Trial Using a Modified COG ABFM Regimen Backbone to Investigate Capizzi Escalating Methotrexate Versus High Dose Methotrexate in Children With Newly Diagnosed T-cell Lymphoblastic Lymphoma), which is not on this map. Cited by 20 papers.

0numbers the graph read from it
0cells of the map it votes in
20citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05681260 phase3recruitingnot on this mapstarted 2023, after this paper: background citation

A Randomized Trial Using a Modified COG ABFM Regimen Backbone to Investigate Capizzi Escalating Methotrexate Versus High Dose Methotrexate in Children With Newly Diagnosed T-cell Lymphoblastic Lymphoma (T-LBL)

TypeinterventionalSponsorChildren's Cancer Group, ChinaRan2023 to 2029Enrolled200ConditionsT-cell Lymphoblastic LymphomaArmsPrednisone,Vincristine, Pegylated-asparaginase, Bortezomib,Cytarabine, Cyclophosphamide, Daunorubicin, 6-mercaptopurine, methotrexate, Dexamethasone, Doxorubicin, Prednisone,Vincristine, Pegylated-asparaginase, Bortezomib,Cytarabine, Cyclophosphamide, Daunorubicin, 6-mercaptopurine, methotrexate, Dexamethasone, Doxorubicin, Vindesine, Etoposide, Ifosfamide
3 · Its place in the literature

Who cites it

20 citing papers in PubMed.

  1. Review
  2. Article
  3. Review
  4. Therapeutic targeting of senescent cells in the CNS.Nature reviews. Drug discovery · 2024
    Review
  5. Impact of Age on Pharmacogenomics and Treatment Outcomes of B-Cell Acute Lymphoblastic Leukemia.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2024
    Article
  6. Article
  7. Article
  8. Challenges to successful outcomes in AYAs with ALL and potential solutions.Hematology. American Society of Hematology. Education Program · 2023
    Article
  9. Review
  10. Review
  11. Article
  12. Review
  13. Article
  14. Article
  15. Article
  16. Article
  17. Preferential Activity ofEvidence-based complementary and alternative medicine : eCAM · 2020
    Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

S LaukkanenTampere Center for Child Health Research, University of Tampere, and Tampere University Hospital, Tampere, Finland.
T GrönroosTampere Center for Child Health Research, University of Tampere, and Tampere University Hospital, Tampere, Finland.
P PölönenInstitute of Biomedicine, School of Medicine, University of Eastern Finland, Kuopio, Finland.
H KuusanmäkiInstitute for Molecular Medicine Finland FIMM, University of Helsinki, Helsinki, Finland.
J MehtonenInstitute of Biomedicine, School of Medicine, University of Eastern Finland, Kuopio, Finland.
J CloosDepartment of Pediatric Oncology/Hematology, VU University Medical Center, Amsterdam, The Netherlands.
G OssenkoppeleDepartment of Hematology, VU University Medical Center, Amsterdam, The Netherlands.
B GjertsenDepartment of Clinical Science, Hematology Section, University of Bergen, Bergen, Norway.
B ØysteinDepartment of Clinical Science, Hematology Section, University of Bergen, Bergen, Norway.
C HeckmanInstitute for Molecular Medicine Finland FIMM, University of Helsinki, Helsinki, Finland.
M HeinäniemiInstitute of Biomedicine, School of Medicine, University of Eastern Finland, Kuopio, Finland.
M KontroDepartment of Hematology, Hematology Research Unit Helsinki, University of Helsinki, and Helsinki University Central Hospital Cancer Center, Helsinki, Finland.
O LohiTampere Center for Child Health Research, University of Tampere, and Tampere University Hospital, Tampere, Finland.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

DasatinibDose-Response Relationship, DrugDrug Screening Assays, AntitumorHumansPrecursor T-Cell Lymphoblastic Leukemia-LymphomaDasatinib

Identifiers

PMID28885610
PMCPMC5709756

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.